Evidence map›Paper›PMID 33954054›Full record

ArticlePeerJ2021

Outcomes of hospitalized patients with COVID-19 according to level of frailty.

Eva María Andrés-Esteban, Manuel Quintana-Diaz, Karen Lizzette Ramírez-Cervantes, Irene Benayas-Peña, Alberto Silva-Obregón, Rosa Magallón-Botaya, Ivan Santolalla-Arnedo, Raúl Juárez-Vela, Vicente Gea-Caballero

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Long COVID and hypertension-related disorders: a report from the Japanese Society of Hypertension Project Team on COVID-19.Hypertension research : official journal of the Japanese Society of Hypertension · 2023
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

Eva María Andrés-EstebanGrupo PBM, Instituto de Investigación-IdiPaz, Madrid, Madrid, Spain.
Manuel Quintana-DiazGrupo PBM, Instituto de Investigación-IdiPaz, Madrid, Madrid, Spain.ORCID 0000-0003-4852-4148
Karen Lizzette Ramírez-CervantesGrupo PBM, Instituto de Investigación-IdiPaz, Madrid, Madrid, Spain.
Irene Benayas-PeñaGrupo PBM, Instituto de Investigación-IdiPaz, Madrid, Madrid, Spain.
Alberto Silva-ObregónGrupo PBM, Instituto de Investigación-IdiPaz, Madrid, Madrid, Spain.ORCID 0000-0002-6479-4220
Rosa Magallón-BotayaDepartamento de Medicina, Psiquiatría y Dermatología, Universidad de Zaragoza, Zargoza, Aragón, Spain.ORCID 0000-0002-3006-5353
Ivan Santolalla-ArnedoUniversidad de La Rioja, Centro de Investigación Biomédica de La Rioja-CIBIR, Logroño, La Rioja, Spain.ORCID 0000-0001-6705-7122
Raúl Juárez-VelaGrupo PBM, Instituto de Investigación-IdiPaz, Madrid, Madrid, Spain.
Vicente Gea-CaballeroNursing School La Fe., Adscript center of Universidad de Valencia., Valencia, Valencia, Spain.ORCID 0000-0001-8607-3195
Universidad de La Rioja · ESAsociación Española Contra el Cáncer · ESHospital La Paz Institute for Health Research · ESHospital Universitario de Guadalajara · ESHospital Universitario La Paz · ESUniversidad de Zaragoza · ESUniversidad Rey Juan Carlos · ESUniversitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe complications from coronavirus disease 2019 (COVID-19) have been the subject of study in diverse scientific reports. However, many aspects that influence the prognosis of the disease are still unknown, such as frailty, which inherently reduces resistance to disease and makes people more vulnerable. This study aimed to explore the complications of COVID-19 in patients admitted to a third-level hospital and to evaluate the relationship between these complications and frailty.

methodsAn observational, descriptive, prospective study was performed in 2020. A sample of 254 patients from a database of 3,112 patients admitted to a high-level hospital in Madrid, Spain was analyzed. To assess frailty (independent variable) the Clinical Frailty Scale (CFS) was used. The outcome variables were sociodemographic and clinical, which included complications, length of stay, intensive care unit (ICU) admission and prognosis.

resultsA total of 13.39% of the patients were pre-frail and 17.32% were frail. Frail individuals had a shorter hospital stay, less ICU admission, higher mortality and delirium, with statistical significance.

conclusionFrailty assessment is a crucial approach in patients with COVID-19, given a higher mortality rate has been demonstrated amongst frail patients. The CFS could be a predictor of mortality in COVID-19.

Indexed as

AgedComplicationsCoronavirus infectionCOVID-19FrailtyMortalityPrognosisSARS-CoV-2

Identifiers

PMID33954054
PMCPMC8051355
OpenAlexW3152816352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.